- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Ryan Haumschild, PharmD, Discusses Plan to Increase Biosimilar Utilization
We sat down with Ryan Haumschild, PharmD, director of pharmacy at Emory Healthcare, to discuss how this program has empowered biosimilar utilization within Emory and how Emory’s initiatives could be implemented on a larger scale.
After a study revealed the hesitancies of many Emory Healthcare providers to use biosimilars, Ryan Haumschild, PharmD, director of pharmacy at Emory Healthcare, helped devise a new plan to increase utilization rates in order to control the total cost of care for patients as well as improve the baseline understand of biosimilars by developing comprehensive educational materials.
We sat down with Haumschild to discuss how this program has empowered biosimilar utilization within Emory and how Emory’s initiatives could be implemented on a larger scale.
To learn more about Emory Healthcare, visit emoryhealthcare.org.
Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals
February 9th 2025In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends shaping the health care landscape.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.
